Retatrutide vs Tirzepatide
Retatrutide and tirzepatide sit at the cutting edge of incretin research, but they hit a different number of receptors. Tirzepatide is a dual GIP/GLP-1 agonist, while retatrutide adds a third arm — glucagon — making it a triple agonist. That extra glucagon activity is the headline difference researchers care about.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Compound class | Triple GIP/GLP-1/glucagon agonist | Dual GIP/GLP-1 receptor agonist |
| Primary target | GIP + GLP-1 + glucagon receptors | GIP + GLP-1 receptors |
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Administration | Weekly subcutaneous | Weekly subcutaneous |
| Research focus | Energy expenditure & metabolic endpoints | Body-composition & glycemic endpoints |
Key differences
- Receptor coverage: tirzepatide activates GIP and GLP-1; retatrutide adds glucagon-receptor agonism on top, which is associated in the literature with increased energy expenditure.
- Magnitude of effect: early retatrutide data report some of the largest body-composition changes of any compound in the class, whereas tirzepatide has the deeper, more mature dataset.
- Titration: both are dosed weekly and titrated slowly, but retatrutide research protocols typically start very low (around 1 mg) because of the added glucagon signaling.
- Maturity: tirzepatide is a well-characterized, widely studied molecule; retatrutide is newer and still early in its research timeline.
Which is right for your research?
Choose tirzepatide when you want the more established dual-agonist dataset, and retatrutide when the research question specifically involves triple-agonist glucagon activity and maximal metabolic effect. Both are weekly subcutaneous compounds that titrate up gradually.
Frequently asked questions
What is the main difference between retatrutide and tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist; retatrutide is a triple agonist that also activates the glucagon receptor. The glucagon arm is the defining mechanistic difference.
Are retatrutide and tirzepatide dosed the same way?
Both are weekly subcutaneous compounds that are titrated upward over time. Retatrutide research protocols generally start at a lower milligram dose because of its added glucagon activity.
Which is newer?
Retatrutide is the newer molecule and is earlier in its research timeline, while tirzepatide has a larger and more mature body of published data.
For Research Use Only. All products are sold as research chemicals for in-vitro laboratory study. Not for human consumption, medical, veterinary, or household use.